Class: First Generation Antihistamines
ATC Class: R06AX02
VA Class: AH107
Chemical Name: 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride
Molecular Formula: C21H21N•HCl
CAS Number: 41354-29-4
Special Alerts:
[Posted 10/09/2008] FDA notified healthcare professionals and consumers that the Consumer Healthcare Products Association (CHPA) is voluntarily modifying the product labels for consumers of over the counter (OTC) cough and cold medicines to state “do not use” in children under 4 years of age. FDA supports CHPA members to help prevent and reduce misuse and to better inform consumers about the safe and effective use of these products for children. FDA continues to assess the safety and efficacy of these products and to revise its OTC list of approved ingredients and amounts for these medicines. Parents and care givers should adhere to the dosage instructions and warnings on the label that accompanies OTC cough and cold medications before giving the product to children, and should consult their healthcare professionals if they have any questions or concerns. For more information visit the FDA website at: and .
Introduction
First generation antihistamine; serotonin antagonist;5 6 27 40 43 50 51 structurally and pharmacologically related to azatadine.1 5
Uses for Cyproheptadine Hydrochloride
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Allergic Conditions
Treatment of cold urticaria.5 11 12 13 74 75
Symptomatic relief of perennial (nonseasonal) and seasonal (e.g., hay fever) allergic rhinitis.74 75 c
Management of nonallergic (vasomotor) rhinitis.74 75
Management of allergic conjunctivitis caused by foods or inhaled allergens.74 75 c
Management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.74 75
Treatment of dermatographism.74 75 c
Amelioration of allergic reactions to blood or plasma.74 75 c
Adjunct to epinephrine and other standard measures for management of anaphylactic reactions after acute manifestations have been controlled.74 75
Cushing’s Syndrome
Has been effective in some patients for the treatment of Cushing’s syndrome† secondary to pituitary disorders;14 15 16 17 18 19 20 21 48 52 53 63 however, in most patients, other therapy (e.g., surgery, radiation therapy) is preferred.21 39 48
Sexual Dysfunction
Has been effective for the management of inhibited male or female orgasm† (anorgasmy) induced by tricyclic antidepressants,55 57 58 66 MAO inhibitors,54 56 fluoxetine,68 or antipsychotic agents.56 However, consider the potential for interactions between these drugs and cyproheptadine.5 66 (See Interactions.)
Anorexia Nervosa
Has been shown to stimulate appetite and weight gain in children32 33 and adults;34 35 36 however, few indications for clinical use.40 May be of some value in the treatment of anorexia nervosa†;37 38 41 46 47 59 60 may be more effective in nonbulimic patients than in those who are bulimic.59
Headache
Reportedly has been effective in some patients for the management of vascular headaches† (e.g., migraine).30 31 43 44 71 Efficacy for prophylaxis of migraine not established in randomized controlled studies, but some experts consider the drug to be effective based on consensus and clinical experience.71
Cyproheptadine Hydrochloride Dosage and Administration
Administration
Oral Administration
Administer orally as tablets or oral solution.74 75
Dosage
Available as cyproheptadine hydrochloride; dosage expressed in terms of the salt.74 75
Pediatric Patients
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Allergic Conditions
Oral
Children 2–6 years of age: Usual dosage is 2 mg 2 or 3 times daily; adjust as needed based on the size and response of the patient, up to maximum of 12 mg daily.5 74 75 (See Pediatric Use under Cautions.)
Children 7–14 years of age: Usual dosage is 4 mg 2 or 3 times daily; adjust as needed based on the size and response of the patient, up to maximum of 16 mg daily.5 74 75
Adolescents ≥15 years of age: Initially, 4 mg 3 times daily; adjust based on the size and response of the patient, up to 0.5 mg/kg daily.74 75 Dosage range: 4–20 mg daily; most patients require 12–16 mg daily.74 75
Alternatively, children ≥2 years of age may receive 0.25 mg/kg or 8 mg/m2 daily in divided doses.5 74 75
Anorexia Nervosa†
Oral
Adolescents ≥13 years of age: Dosage of 2 mg 4 times daily, increased gradually over a 3-week period to up to 8 mg 4 times daily, has been used.38 46 47 59
Adults
Allergic Conditions
Oral
Initially, 4 mg 3 times daily; adjust as needed based on the size and response of the patient, up to 0.5 mg/kg daily.5 74 75
Dosage range: 4–20 mg daily; most patients require 12–16 mg daily.5 74 75 Some patients may require up to 32 mg daily.5 74 75
Cushing’s Syndrome†
Oral
Initially, 8 mg daily in divided doses; gradually increase dosage to up to 24 mg daily in divided doses.14 17 18 21 48 52
Anorexia Nervosa†
Oral
Dosage of 2 mg 4 times daily, increased gradually over a 3-week period to up to 8 mg 4 times daily, has been used.38 46 47 59
Prescribing Limits
Pediatric Patients
Allergic Conditions
Oral
Children 2–6 years of age: Maximum 12 mg daily.74 75
Children 7–14 years of age: Maximum 16 mg daily.74 75
Adolescents ≥15 years of age: Maximum 0.5 mg/kg daily.74 75
Anorexia Nervosa†
Oral
Adolescents ≥13 years of age: Maximum 32 mg daily.38 46 47 59
Adults
Allergic Conditions
Oral
Maximum 0.5 mg/kg daily.74 75
Cushing’s Syndrome†
Oral
Maximum 24 mg daily.14 17 18 21 48 52
Anorexia Nervosa†
Oral
Maximum 32 mg daily.38 46 47 59
Special Populations
Geriatric Patients
Select dosage with caution, starting at the lower end of the usual dosage range.5 74 (See Geriatric Use under Cautions.)
Cautions for Cyproheptadine Hydrochloride
Contraindications
Neonates and premature infants.74 75
Women who are breast-feeding.74 75 (See Lactation and also Pediatric Use under Cautions.)
Known hypersensitivity to cyproheptadine or other drugs with similar chemical structures.74 75
Patients receiving MAO inhibitor therapy.74 75 (See Interactions.)
Known history of angle-closure glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction.74 75
Debilitated geriatric patients.74 75
Warnings/Precautions
Warnings
CNS Effects
Risk of marked drowsiness.74 75 c Caution required when performing hazardous activities requiring mental alertness and motor coordination (e.g., driving a motor vehicle, operating machinery).74 75 c
Possible excitability (especially in children).74 75 c (See Pediatric Use under Cautions.)
Concurrent use of other CNS depressants may have additive CNS depressant effects.74 75 c (See Interactions.)
General Precautions
Concomitant Diseases
Because of anticholinergic effects, use with caution in patients with increased intraocular pressure, active or history of respiratory disease (e.g., bronchial asthma), hyperthyroidism, or cardiovascular disease (e.g., hypertension).74 75 c (See Contraindications.) Use of antihistamines generally not recommended in asthmatics who previously experienced a serious antihistamine-induced adverse bronchopulmonary effect.
Specific Populations
Pregnancy
Category B.74 75
Lactation
Not known whether cyproheptadine is distributed into milk.5 74
Because of potential for serious adverse effects in nursing infants, discontinue nursing or the drug.5 74 75 (See Pediatric Use under Cautions.)
Pediatric Use
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Contraindicated in neonates and premature infants.74 75
Safety and efficacy of cyproheptadine not established in children <2 years of age.74 75
Risk of overdosage and toxicity (including death) in children <2 years of age receiving OTC preparations containing antihistamines, cough suppressants, expectorants, and nasal decongestants alone or in combination for relief of symptoms of upper respiratory tract infection.72 73 Limited evidence of efficacy for these preparations in this age group; appropriate dosages not established.72 Therefore, FDA recommended not to use such preparations in children <2 years of age; safety and efficacy in older children currently under evaluation. Because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations recently agreed to voluntarily revise the product labeling to state that such preparations should not be used in children <4 years of age. During the transition period, some preparations on pharmacy shelves will have the new recommendation (“do not use in children <4 years of age”), while others will have the previous recommendation (“do not use in children <2 years of age”). FDA recommends that parents and caregivers adhere to dosage instructions and warnings on the product labeling that accompanies the preparation and consult a clinician about any concerns. Clinicians should ask caregivers about use of OTC cough/cold preparations to avoid overdosage.
Cyproheptadine overdosage, particularly in infants and young children, may produce hallucinations, CNS depression, seizures, respiratory and cardiac arrest, and death.74 75
Possible paradoxical excitement (e.g., restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures), especially in young children.74 75 c Central anticholinergic syndrome (e.g., hallucinations, agitation, confusion) has occurred.
Geriatric Use
Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; clinical experience has not revealed age-related differences.5 74 Select dosage with caution (usually starting at low end of dosage range) because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.5 74
Possible increased risk of dizziness, sedation, and hypotension in geriatric patients.74 75
Contraindicated in debilitated geriatric patients.74 75
Common Adverse Effects
Sedation,74 75 sleepiness (often transient),74 75 dizziness,74 75 disturbed coordination,74 75 restlessness,74 75 excitation.74 75
Interactions for Cyproheptadine Hydrochloride
Specific Drugs and Laboratory Tests
Drug | Interaction | Comments |
|---|---|---|
CNS depressants (e.g., alcohol, hypnotics, sedatives, tranquilizers) | Possible additive CNS depression74 75 c | Use caution to avoid overdosage;c advise patient to avoid alcohol |
Fluoxetine | Reversal of fluoxetine's antidepressant effects reported in limited number of patients, possibly due to inhibition of fluoxetine's serotonergic effects69 70 | |
MAO inhibitors | MAO inhibitors prolong and intensify anticholinergic effects of antihistamines74 75 c | |
Test, antigen or histamine | Inhalation-challenge testing with histamine or antigen: Possible suppression of test response Antigen skin testing: Possible suppression of wheal and flare reactions |
Cyproheptadine Hydrochloride Pharmacokinetics
Absorption
Bioavailability
Well absorbed following oral administration.1 7
Distribution
Extent
Distribution into human body tissues and fluids has not been characterized.7
Elimination
Metabolism
Appears to be almost completely metabolized,7 8 9 10 principally to the quaternary ammonium glucuronide conjugate.8 9 10
Elimination Route
Principally in urine, as conjugates; 7 8 9 10 also in feces following oral administration.5 7 74 75
Special Populations
Elimination is reduced in renal insufficiency.5 74 75
Stability
Storage
Oral
Solution
15–30°C.75
Tablets
Tightly closed container at 15–30°C.74
ActionsActions
Has potent antihistaminic and serotonin antagonist properties; also has anticholinergic and sedative effects5 6 40 50 51 and reportedly has calcium-channel blocking activity.42
Advice to Patients
Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
Risk of drowsiness;74 75 c avoid alcohol and use caution when engaging in activities requiring mental alertness and motor coordination (e.g., driving a motor vehicle, operating machinery).74 75 c
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.74 75
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.74 75
Importance of informing patients of other important precautionary information.74 75 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Solution | 2 mg/5 mL* | Cyproheptadine Hydrochloride Syrup | |
Tablets | 4 mg* | Cyproheptadine Hydrochloride Tablets |
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Cyproheptadine HCl 2MG/5ML Syrup (ACTAVIS MID ATLANTIC): 120/$18.99 or 360/$38.97
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions November 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Schering. Optimine prescribing information. In: Huff BB, ed. Physicians’ desk reference. 38th ed. Oradell, NJ: Medical Economics Company Inc; 1984:1795-7.
2. The United States pharmacopeia, 21st rev, and The national formulary, 16th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1984:267, 1450, 1484.
3. Hoffman JP (Merck, Sharp and Dohme): Personal communication; 1978 May 15.
4. United States Pharmacopeia Dispensing Information (USP DI). Vol I. Drug information for the health care provider. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1983:142.
5. Merck & Co. Periactin (cyproheptadine) tablets and syrup prescribing information. West Point, PA; 1999 Sept.
6. Stone CA, Wenger HC, Ludden CT et al. Antiserotonin-antihistaminic properties of cyproheptadine. J Pharmacol Exp Ther. 1961; 131:73-84.
7. Hintze KL, Wold JS, Fischer LJ. Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite. Drug Metab Dispos. 1975; 3:1-9. [IDIS 50715] [PubMed 234828]
8. Porter CC, Arison BH, Gruber VF et al. Human metabolism of cyproheptadine. Drug Metab Dispos. 1975; 3:189-97. [IDIS 52901] [PubMed 238818]
9. Kennedy KA, Halmi KA, Fischer LJ. Urinary excretion of a quaternary ammonium glucuronide metabolite of cyproheptadine in humans undergoing chronic drug therapy. Life Sci. 1977; 21:1813-20. [PubMed 604709]
10. Fischer LJ, Thies RL, Charkowski D et al. Formation and urinary excretion of cyproheptadine glucuronide in monkeys, chimpanzees, and humans. Drug Metab Dispos. 1980; 8:422-4. [IDIS 128861] [PubMed 6109610]
11. Wanderer AA, St. Pierre JP, Ellis EF. Primary acquired cold urticaria: double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. Arch Dermatol. 1977; 113:1375-7. [IDIS 89712] [PubMed 334082]
12. Sigler RW, Evans R III, Horakova Z et al. The role of cyproheptadine in the treatment of cold urticaria. J Allergy Clin Immunol. 1980; 65:309-12. [IDIS 112895] [PubMed 6102102]
13. Buckley RH, Mathews KP. Common “allergic” skin diseases. JAMA. 1982; 248:2611-22. [IDIS 160684] [PubMed 7143623]
14. Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing’s disease. N Engl J Med. 1975; 293:893-6. [IDIS 55425] [PubMed 1177986]
15. Krieger DT. Cyproheptadine for pituitary disorders. N Engl J Med. 1976; 295:394-5. [PubMed 934231]
16. Grant DB, Atherden SM. Cushing’s disease presenting with growth failure: clinical remission during cyproheptadine therapy. Arch Dis Child. 1979; 54:466-8. [IDIS 99588] [PubMed 475431]
17. Hsu TH, Gann DS, Tsan KW et al. Cyproheptadine in the control of Cushing’s disease. Johns Hopkins Med J. 1981; 149:77-83. [IDIS 137249] [PubMed 6265685]
18. Jimenez-Alonso J, Munoz-Avila J, Jaimez L et al. Cyproheptadine-induced remission of Cushing’s disease due to pituitary basophil adenoma. Drug Intell Clin Pharm. 1982; 16:962-5. [IDIS 161163] [PubMed 6295736]
19. Griffith DN, Rose EJ. Pregnancy after cyproheptadine treatment for Cushing’s disease. N Engl J Med. 1981; 305:893-4. [IDIS 137895] [PubMed 7278892]
20. Kasperlik-Zaluska A, Migdalska B, Hartwig W et al. Two pregnancies in a woman with Cushing’s syndrome treated with cyproheptadine: case report. Br J Obstet Gynaecol. 1980; 87:1171-3. [PubMed 7437385]
21. Gold EM. The Cushing syndromes: changing views of diagnosis and treatment. Ann Intern Med. 1979; 90:829-44. [IDIS 95709] [PubMed 219743]
22. Hartwig W, Kasperlik-Zaluska A, Wilczynska J et al. Cyproheptadine for pituitary disorders. N Engl J Med. 1976; 295:394. [PubMed 934231]
23. Krieger DT, Condon EM. Cyproheptadine treatment of Nelson’s syndrome: restoration of plasma ACTH circadian periodicity and reversal of response to TRF. J Clin Endocrinol Metab. 1978; 46:349-52. [IDIS 101716] [PubMed 220278]
24. Aronin N, Krieger DT. Sustained remission of Nelson’s syndrome after stopping cyproheptadine treatment. N Engl J Med. 1980; 302:453-5. [IDIS 110686] [PubMed 6243392]
25. Hsu TH. Management of virilizing congenital adrenal hyperplasia with cyproheptadine. Ann Intern Med. 1980; 92:628-30. [IDIS 113155] [PubMed 7387003]
26. Wortsman J, Soler NG, Hirschowitz J. Cyproheptadine in the management of the galactorrhea-amenorrhea syndrome. Ann Intern Med. 1979; 90:923-5. [IDIS 96572] [PubMed 571691]
27. Vroom FQ, Brown RE, Dempsey H et al. Studies on several possible antiserotonin compounds in a patient with the functioning carcinoid syndrome. Ann Intern Med. 1962; 56:941-5. [PubMed 13926919]
28. Berry EM, Maunder C, Wilson M. Carcinoid myopathy and treatment with cyproheptadine (Periactin). Gut. 1974; 15:34-8. [IDIS 45837] [PubMed 4274414]
29. Harris AL, Smith IE. Regression of carcinoid tumour with cyproheptadine. BMJ. 1982; 285:475. [IDIS 155028] [PubMed 6809131]
30. Curran DA, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry. 1964; 27:463-9. [PubMed 14213477]
31. Lance JW, Curran DA, Anthony M. Investigations into the mechanism and treatment of chronic headache. Med J Aust. 1965; 2:909-14. [PubMed 5322372]
32. Lavenstein AF, Decaney EP, Lasagna L et al. Effect of cyproheptadine on asthmatic children. JAMA. 1962; 180:912-6. [PubMed 14462919]
33. Bergen SS. Appetite stimulating properties of cyproheptadine. Am J Dis Child. 1964; 108:270-3. [PubMed 14168064]
34. Noble RE. Effect of cyproheptadine on appetite and weight gain in adults. JAMA. 1969; 209:2054-5. [PubMed 4897366]
35. Silverstone T, Schuyler D. The effect of cyproheptadine on hunger, calorie intake, and body weight in man. Psychopharmacologia. 1975; 40:335-40. [PubMed 1096217]
36. Pawlowski GJ. Cyproheptadine: weight-gain and appetite stimulation in essential anorexic adults. Curr Ther Res Clin Exp. 1975; 18:673-8. [PubMed 812645]
37. Goldberg SC, Halmi KA, Eckert ED. Cyproheptadine in anorexia nervosa. Br J Psychiatry. 1979; 134:67-70. [PubMed 367480]
38. Halmi KA, Eckert E, Falk JR. Cyproheptadine for anorexia nerovsa. Lancet. 1982; 1:1357-8. [IDIS 151434] [PubMed 6123657]
39. Vaughan GM, Taylor TJ. Cushing’s syndrome. In: Conn HF, ed. Current therapy: latest approved methods of treatment for the practicing physician, 1983. Philadelphia: WB Saunders Company; 1983:472-7.
40. Anon. Cyproheptadine. Lancet. 1978; 1:367-8.
41. Goldberg SC, Eckert ED, Halmi KA et al. Effects of cyproheptadine on symptoms and attitudes in anorexia nervosa. Arch Gen Psychiatry. 1980; 37:1083. [IDIS 123856] [PubMed 7416909]
42. Peroutka SJ, Allen GS. The calcium antagonist properties of cyproheptadine: implications for antimigraine action. Neurology. 1984; 34:304-9. [PubMed 6538269]
43. Lance JW, Anthony M, Somerville B. Comparative trial of serotonin antagonists in the management of migraine. Br Med J. 1970; 1:327-30. [PubMed 4906701]
44. Bille B, Ludvigsson J, Sanner G. Prophylaxis of migraine in children. Headache. 1977; 17:61-3. [PubMed 324951]
45. Greenberger P, Patterson R. Safety of therapy for allergic symptoms during pregnancy. Ann Intern Med. 1978; 89:234-7. [PubMed 28058]
46. Falk JR, Halmi KA, Tyron WW. Activity measures in anorexia nervosa. Arch Gen Psychiatry. 1985; 42:811-4. [PubMed 4015326]
47. Herzog DB, Copeland PM. Eating disorders. N Engl J Med. 1985; 313:295-303. [IDIS 202663] [PubMed 2861566]
48. Burch WM. Cushing’s disease: a review. Arch Intern Med. 1985; 145:1106-11. [IDIS 200607] [PubMed 3923962]
49. Kaplowitz PB, Jennings S. Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. J Pediatr. 1987; 110:140-3. [IDIS 225707] [PubMed 3794875]
50. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:605-38.
51. Anthony M. Serotonin antagonists. Aust N Z J Med. 1984; 6:888-95.
52. Wiesen M, Ross F, Kreiger DT. Prolonged remission of a case of Cushing’s disease following cessation of cyproheptadine therapy. Acta Endocrinol (Copenh). 1983; 102:436-8. [PubMed 6829265]
53. Couch RM, Smail PJ, Dean HJ et al. Prolonged remission of Cushing disease after treatment with cyproheptadine. J Pediatr. 1984; 104:906-8. [IDIS 186484] [PubMed 6327962]
54. DeCastro RM. Reversal of MAOI-induced anorgasmia with cyproheptadine. Am J Psychiatry. 1985; 142:783. [IDIS 200783] [PubMed 4039897]
55. Riley AJ, Riley EJ. Cyproheptadine and antidepressant-induced anorgasmia. Br J Psychiatry. 1986; 148:217-8. [PubMed 3697592]
56. Jeffries JJ. Cyproheptadine and drug-induced anorgasmia. Can J Psychiatry. 1987; 32:79. [PubMed 2880654]
57. Sovner R. Treatment of tricyclic antidepressant-induced orgasmic inhibition with cyproheptadine. J Clin Psychopharmacol. 1984; 4:169. [PubMed 6736278]
58. Steele TE, Howell EF. Cyproheptadine for imipramine-induced anorgasmia. J Clin Psychopharmacol. 1986; 6:326-7. [IDIS 221973] [PubMed 3771824]
59. Halmi KA, Eckert E, LaDu TJ et al. Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986; 43:177-81. [IDIS 212256] [PubMed 3511877]
60. Johnson C, Stuckey M, Mitchell J. Psychopharmacological treatment of anorexia nervosa and bulimia: review and synthesis. J Nerv Ment Dis. 1983; 171:524-34. [PubMed 6310046]
61. Mylan Pharmaceuticals Inc. Cyproheptadine hydrochloride tablets, USP prescribing information. Morgantown, WV; 1985 Feb.
62. Merck Sharp & Dohme. Periactin prescribing information. In: Huff BB, ed. Physicians’ desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc; 1987 (Suppl A):A43.
63. Khir ASM, How J, Bewsher PD. Successful pregnancy after cyproheptadine treatment for Cushing’s disease. Eur J Obstet Gynecol Reprod Biol. 1982; 13:343-7. [PubMed 7128894]
64. Padfield NL. Carcinoid syndrome: comparison of pretreatment regimes in the same patient. Ann R Coll Surg Engl. 1987; 69:16-7. [PubMed 2952043]
65. Kvols LK. Metastatic carcinoid tumors and the carcinoid syndrome: a selective review of chemotherapy and hormonal therapy. Am J Med. 1986; 81(Suppl 6B):49-55. [IDIS 224868] [PubMed 2432781]
66. Pontius EB. Case report of an anticholinergic crisis associated with cyproheptadine treatment of desipramine-induced anorgasmia. J Clin Psychopharmacol. 1988; 8:230-1. [IDIS 242985] [PubMed 3379154]
67. Merck Sharp & Dohme. Periactin tablets and syrup prescribing information. In: Physician’s desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1720-1.
68. McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatry. 1990; 51:383-4. [IDIS 272903] [PubMed 2211550]
69. Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry. 1991; 52:163-4. [IDIS 281251] [PubMed 2016249]
70. Fluoxetine/cyproheptadine. In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1992(Jan):344c.
71. Ramadan NM, Silberstein SD, Freitag F et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. St. Paul, MN; 2001. From the American Academy of Neurology web site: ().
72. Srinivasan A, Budnitz D, Shehab N et al. Infant deaths associated with cough and cold medications—two states, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56:1-4. [PubMed 17218934]
73. Food and Drug Administration. Cough and cold medications in children less than two years of age. Rockville, MD; 2007 Jan 12. From FDA website ().
74. Corepharma LLC. Cyproheptadine hydrochloride (Cyproheptadine Hydrochloride) tablet prescribing information. Middlesex, NJ; 2006 Jun.
75. Alpharma USPD. Cyproheptadine hydrochloride oral solution prescribing information. Baltimore, MD; 2005 Jun.
c. AHFS drug information 2007. McEvoy GK, ed. Antihistamines general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1-8.
More Cyproheptadine Hydrochloride resources
- Cyproheptadine Hydrochloride Side Effects (in more detail)
- Cyproheptadine Hydrochloride Use in Pregnancy & Breastfeeding
- Drug Images
- Cyproheptadine Hydrochloride Drug Interactions
- Cyproheptadine Hydrochloride Support Group
- 20 Reviews for Cyproheptadine Hydrochloride - Add your own review/rating
- Cyproheptadine Prescribing Information (FDA)
- cyproheptadine Concise Consumer Information (Cerner Multum)
- Cyproheptadine MedFacts Consumer Leaflet (Wolters Kluwer)
Compare Cyproheptadine Hydrochloride with other medications
- Allergic Reactions
- Anorexia
- Anorexia Nervosa
- Cluster Headaches
- Cushing's Syndrome
- Failure to Thrive
- Hay Fever
- Migraine
- Pruritus
- Sexual Dysfunction, SSRI Induced
- Urticaria
No comments:
Post a Comment